NASH and COVID-19
Sign Up For Email Notifications when more COVID episodes are available:
Our COVID response includes multiple episodes discussing the impact of COVID on the liver, and how healthcare and treatment changes because of the disruption of COVID-19. We will maintain this list of COVID-related episodes to stay current:
Ep. 1 – COVID CHAOS
Navigating NAFLD/NASH clinical trials through the pandemic
Ep. 3 – C-SUITE COVID-19 CHALLENGES
Critical considerations for companies developing NASH drugs
Ep. 4 – WHEN YOU GET TO A FORK IN THE ROAD
Three possible scenarios for development of the NASH market.
Ep. 11 – Crystal ball tells us the most important story of the summer
CONSENSUS: the big story will be the regrowth of COVID-19 in the US and its implications
Ep. 14 – Respect for the liver
NASH is not merely a byproduct of obesity.
Ep. 23 – Digital ILC Day Three Highlights: Late breakers, COVID and more
Day Three into EASL Digital ILC 2020 – SurfingNASH’s Digital ILC coverage ends with three late-breaking drug presentations, a discussion of EASL’s COVID efforts, and insights on patient management.
Ep. 27 – Crystal Ball Tells Us The Most Important Stories Of Autumn
The Surfers discuss four issues that are likely to affect how our thinking about NASH diagnosis, education, and treatment might evolve over the next three months.
Ep. 29 – COVID-19 and The Liver… “It’s Complicated”
Matt Kelly, Chief Innovation Officer at Perspectum, Ltd., joins the Surfers to the discuss early findings from the COVERSCAN study which looks at the relationship between COVID-19 infection and major end organ systems.
Ep. 30 – Six Months In: How COVID-19 Has Changed Our World!
On the six-month anniversary of SurfingNASH’s first episode, the Surfers stop to consider how much has changed for NASH stakeholders since April
